Connect your AI

Nuvation Bio NUVB Liability Related To Revenue Interest Financing Agreement

Liability Related To Revenue Interest Financing Agreement at other companies

BioCryst PharmaceuticalsBCRX

$40.32M+17.5%

uniQureQURE

$482.33M+8.0%

Kodiak Sciences IncKOD

$100M0.0%

Ultragenyx PharmaceuticalRARE

$1.13B+42.1%

BioCryst PharmaceuticalsBCRX

$407.18M-12.7%

Arrowhead ResearchARWR

$383.83M+9.0%

Other financials

Income statement

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

Market cap$2.1B+150%

Enterprise value$2.03B+154%

P/S14.7×-62.0×

Profitability

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept nuvb:LiabilityRelatedToRevenueInterestFinancingAgreement.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's liability related to revenue interest financing agreement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Nuvation Bio's liability related to revenue interest financing agreement?: Nuvation Bio (NUVB) reported liability related to revenue interest financing agreement of $7.94M in Q1 2026.
What does liability related to revenue interest financing agreement mean?: This represents the current portion of obligations owed to third parties under revenue interest financing agreements, often referred to as royalty monetization. It indicates the company's commitment to share future product revenues in exchange for upfront capital. Investors track this to understand the near-term cash flow impact of non-dilutive financing arrangements.